Open Label High Dose Ropinirole (Requip) Study for Patients With Parkinson's Disease

Status unconfirmed · Phase 3

Conditions studied: Parkinson's Disease

In brief

The purpose of this research study is to see if subjects with Parkinson's disease who are experiencing motor fluctuations ("on" and "off" states) and dyskinesias (involuntary excessive movements) would benefit from a higher dose of Requip as compared to the maximum FDA approved dose of dopamine agonist drugs (including Requip, Mirapex, and Permax). Requip as used in this study is investigational, which means it has not been approved by the US Food and Drug Administration (FDA) at this dose level.

Key facts

Study ID

NCT00260793

Run by

Agarwal, Pinky, M.D.

People needed

20

Starts

2005-11-01

Last updated by the study team

2006-02-03

Who can join

Age: 25 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must give written informed consent prior to any specific study procedures.
• Males or females; females of childbearing age who are not currently pregnant must agree to use a medically accepted method of contraception throughout the study.
• Age greater than or equal to 25 years.
• Patients must be on a maximum dose of dopamine agonist drug (pergolide 4mg/day, pramipexole 4.5 mg/day or ropinirole 24mg/day).
• Stable dose of all medications for 4 weeks.

You may not qualify if…

• Current hallucinations.
• History of disabling hallucinations or hallucinations in past requiring treatment.
• Troublesome edema (swelling).
• Unstable depression.
• Female who is pregnant or lactating.
• Use of an investigational drug with in the last 30 days.
• Other inclusion or exclusion criteria to be evaluated by the physician.

Where it is running

• Colorado Neurology, P.C. — Englewood, Colorado, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.